Connor, Clark & Lunn Investment Management Ltd. Apellis Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 13,478 shares of APLS stock, worth $370,914. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,478Holding current value
$370,914% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
123MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$336 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$327 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$325 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$276 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$265 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.02B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...